Robert F. Kennedy Jr., in his first time addressing HHS staffers as secretary, lays out his vision for the department. Read ...

Senate committee members heard arguments on a bill that would place a 10-year pause on administering mRNA vaccines in Idaho ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Barclays downgraded Moderna (NASDAQ:MRNA) to Equal Weight from Overweight in a note Tuesday, citing policy risks, a lack of major clinical catalysts, and macroeconomic uncertainties that limit the ...

Vermont has the second lowest state fatality rate in the US (145.3 per 100K; Hawaii 112.6/100K). Mississippi (461.9/100K) and ...

Both the Finnish and the U.S. bird flu vaccines are made by CSL Seqirus but are different vaccines. In the summer, U.S. officials stockpiled 4.8 million doses of the vaccine that officials said was ...

Given the uncertainty around its revenue growth, we advise short-term investors to remain cautious when investing in MRNA ...

Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA stock a buy?

BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.

Scientists are currently working on clinical trials on a norovirus vaccine, and are testing half a dozen potential solutions.

Barclays downgraded Moderna (MRNA) to Equal Weight from Overweight with a price target of $45, down from $111, post the Q4 report. The firm ...